FIP guidelines for dissolution testing of solid oral products joint report of the section for official laboratories and medicines control services and the section of industrial pharmacists of the F.I.P. Correspondence: FIP working group 4: Dissolution and dissolution specifications

Pharmazeutische Industrie

Volumn 59, Issue 9, 1997, Pages 760-766

  Siewert, Martin ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DODECYL SULFATE SODIUM; SODIUM CHLORIDE;

ARTICLE; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; IN VITRO STUDY; LABORATORY TEST; QUALITY CONTROL;

EID: 0030867432     PISSN: 0031711X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. FIP Guidelines for Dissolution Testing of Solid Oral Products Pharm. Ind. 43, 334 (1981)
2. Pernarowski, M., Dissolution Methodology, in: Leeson, L. J., Carstensen, J. T. (eds.), Dissolution Technology, APhA, Washington, DC, 73 (1974)
3. Krowczynski, L., Pharmazie 33, 241 (1978)
4. Dakkuri, A., Shak. A. C, Pharm. Technol. 2, 41 (1982)
5. Lathia, C. D., Banakar, W. V, Drug Dev. Ind. Pharm. 12, 71 (1986)
6. Siewert, M., Associations and Spécifications, in: Blume, H., Grundert-Remy, U, Möller, H. (eds.), Controlled/Modified Release Products. Wissenschaftliche Verlagsgesellschaft, Stuttgart (1991)
7. Wells, C. E., J. Pharm. Sei. 70, 232 (1981)
8. Stricker, H., Acta Pharm. Technol. 30, 113 (1984)
9. Stricker, H., Pharm. Ind. 38, 232 (1976)
10. Dibbern, H. W, Pharm. Ind. 46, 381 (1984)
11. Das SK, Gupta BK, Simulation of physiological pH-time profile in in vitro dissolution study: Relationship between dissolution rate and bioavailability of controlled release dosage form. Drug Dev. Ind. Pharm. 14, 537 (1988)
12. Blume, H., Ali, S. L., Siewert, M., Pharm. Ztg. 129, 983 (1984)
13. Pharm. Sei. EEC Note for Guidance, Quality of Prolonged Release Oral Solid Dosage Forms (1991)
14. Guidelines for Design and Evaluation of Oral Sustained Release Dosage Form, Ministry of Health and Welfare of Japan, Yakuskin-1-5 (1988)
15. Workshop Report, In Vitro and In Vivo Testing and Correlation for Oral Controlled/Modified-Release Dosage Forms, Pharm. Res. 7, 975 (1990)
16. Shah, V. P., Konecny, J. J., Everett, R. L. et al., Pharm. Res. 6 (7), 612 (1989)
17. Shah, V. P., Gurbarg, M., Noory, A. et al., J. Pharm. Sei. 81 (6), 500
18. In-vitro and in-vivo evaluation of dosage forms, USP 23 (1995)
19. Qureshi, S. A., McGilveray, I. J., Pharm. Forum 20 (6), 8565 (1994)
20. Soltero, R. A., Hoover, J. M., Jones, F. T. et al., J. Pharm. Sei. 78, 35 (1989) -
21. U.S. Pharmacopeia 23, Supplement 1, Drug Release 724, 2535 (1995)
22. FIP Working Group 4: Dissolution and Dissolution Specification, Apparatus Suitability Test for the Flow-through Cell (publ. in prep.)
23. Langenbucher, F, Pharm. Ind. 44, 1166 (1982)
24. Langenbucher, F, Pharm. Ind. 44, 1275 (1982)
25. Wagner, J. W, Nelson, F., J. Pharm. Sei. 57, 918 (1968)
26. Loo, J. C. K., Riegelmann, S., J. Pharm. Sei. 57, 918 (1968)
27. Brockmeier, D., Voegele, D., von Hattingberg, H. M., Arzneim. Forsch./Drug Res. 33, 598 (1983)
28. von Hattingberg, H. M., Acta Pharm. Technol. 30, 93 (1984)
29. Cardot, J. M., Beyssac, E., Eur. J. Drug Metab. Pharmacokinet. 18 (1), 113 (1993)
30. Siewert, M., Biointernational 2, 293 (1994)
31. Oberle, R. L., Chen, T.-S., Lloyd, C. et al., Gastroenterology 99, 1275 (1990)
32. Brener, W, Hendrix, T. R., McHugh, P. R., Gastroenterology 85, 76 (1983)
33. Minamin, H., McCallum, R. W, Gastroenterology 86 (6), 1592 (1984)
34. Workshop Report, Scale-Up of Immediate Release Oral Solid Dosage Forms, Pharm. Res. 10, 313 and Eur. J. Pharm. Biopharm. 39 (1), 40 (1993)
35. Workshop II Report, Scale-Up of Oral Extended Release Dosage Forms, Pharm. Res. 10, 1800 and Eur. J. Pharm. Biopharm. 39 (4), 162 (1993)
36. PDA Immediate Release Scale-up and Post Approval Change (SUPAC) Expert Working Group of the Chemistry Manufacturing Controls Coordinating Committee of the Center for Drug Evaluation and Research (1994) Interim Guidance Immediate Release Solid Oral Dosage Forms - Preand Post-Approval Changes
37. Maturu, P. K., Prasad, V. K., Worsley, W. et al., J. Pharm. Sei. 75, 1205 (1986)
38. Wearly, L., Karim, A., Pagone, F. et al., Drug Devl. Ind. Pharm. 14,13 (1988)
39. Karim, A., Importance of Assessing Food Effects in Evaluating Controlled-Release Formulations, in: Yacobi, A., Halperin-Walega, E., Oral Sustained Release Formulations: Design and Evaluation, Pergamon Press, 157 (1988)
40. El-Arini, K., Shiu, G. K., Skelly, J. P., Pharm. Res. 7, 1134 (1986)
41. Macheras, P., Koupparis, M., Tsaprounis, C, Int. J. Pharm. 33, 125 (1986)
42. Junginger, H. E., Verhoeven, J., Peschier, L. J. C., Pharm. Ztg. Wiss. 2, 53 (1990)
43. Krämer, J., Lindauer, R. F., Siewert, M. et al., Eur. J. Drug. Metab. Pharmacokin. 18, 37 (1993)
44. Siewert, M., In vitroDissolution Testing of Oral Controlled Release Products, in: Gundert-Remy, U, Möller, H., Oral Controlled Release Products Therapeutic and Biopharmaceutic Assessment, 139, Wissenschaftliche Verlagsgesellschaft, Stuttgart (1989)
45. Galia, E., Nicolaides, E., Reppas, C. et al. Pharm. Research 13, 262 (1996)
46. Ogata, H. et al, J. Pharmacobio-Dyn 7, 656 (1984)